603387.SHG Getein Biotech Inc
- Market cap
- CNY 4.40B
- P/E
- 14.7x
- P/B
- 1.48x
- ROE
- 10.7%
- Dividend yield
- 2.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603387.SHG undervalued?
Graham number603387.SHG trades 1.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Getein Biotech Inc fundamental analysis
No fundamental analysis for Getein Biotech Inc yet.
Getein Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as myocardium, inflammation, renal function, th…
Full company profileGetein Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Getein Biotech Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 369M | 489M | 686M | 968M | 1.12B | 1.40B | 1.82B | 1.37B | 1.16B | 1.05B | 1.09B |
| Gross Profit | 300M | 400M | 542M | 703M | 709M | 916M | 1.15B | 889M | 790M | 734M | 756M |
| Operating Income | 153M | 223M | 283M | 399M | 378M | 453M | 563M | 307M | 258M | 257M | 274M |
| EBITDA | 178M | 246M | 316M | 425M | 416M | 513M | 642M | 408M | 355M | 325M | 351M |
| Net Income | 138M | 194M | 250M | 340M | 305M | 399M | 499M | 280M | 224M | 221M | 310M |
| EPS | 0.36 | 0.45 | 0.49 | 0.66 | 0.60 | 0.78 | 0.98 | 0.55 | 0.44 | 0.44 | 0.61 |
| Balance Sheet | |||||||||||
| Total Assets | 434M | 1.27B | 1.57B | 2.01B | 2.70B | 3.14B | 3.68B | 3.77B | 3.71B | 3.76B | 3.70B |
| Total Liabilities | 91.1M | 119M | 187M | 326M | 696M | 864M | 1.01B | 1.03B | 986M | 897M | 687M |
| Shareholders' Equity | 340M | 1.14B | 1.35B | 1.62B | 1.84B | 2.11B | 2.48B | 2.56B | 2.62B | 2.75B | 2.91B |
| Cash & Short-term Investments | 26.3M | 301M | 145M | 1.13B | 1.40B | 1.58B | 1.16B | 936M | 1.00B | 314M | 351M |
| Total Debt | - | - | 31.2M | 95.0M | 385M | 496M | 591M | 644M | 577M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 156M | 192M | 187M | 226M | 185M | 432M | 483M | 333M | 423M | 393M | - |
| Capital Expenditure | 39.3M | 61.4M | 111M | 125M | 114M | 180M | 217M | 258M | 156M | 151M | 120M |
| Free Cash Flow | 117M | 131M | 76.4M | 101M | 71.9M | 253M | 266M | 75.1M | 267M | 242M | 261M |
| Ratios | |||||||||||
| ROE | 40.7% | 17.0% | 18.6% | 20.9% | 16.6% | 18.9% | 20.1% | 10.9% | 8.5% | 8.0% | 10.7% |
| ROA | 31.9% | 15.3% | 15.9% | 16.9% | 11.3% | 12.7% | 13.6% | 7.4% | 6.0% | 5.9% | 8.4% |
| Net Profit Margin | 37.5% | 39.7% | 36.4% | 35.1% | 27.1% | 28.5% | 27.4% | 20.4% | 19.2% | 21.0% | 28.3% |
| Debt to Equity | - | - | 0.02x | 0.06x | 0.21x | 0.24x | 0.24x | 0.25x | 0.22x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Getein Biotech Inc dividends
- Dividend yield
- 2.35%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 46.8%
- Ex-dividend date
- Sep 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 103M | 0.20 | 46.8% |
| 2024 | CNY 111M | 0.22 | 49.6% |
| 2023 | CNY 219M | 0.43 | 78.4% |
| 2022 | CNY 123M | 0.24 | 24.7% |
| 2021 | CNY 93.2M | 0.18 | 23.3% |
| 2020 | CNY 104M | 0.21 | 34.2% |
| 2019 | CNY 76.3M | 0.15 | 22.5% |
| 2018 | CNY 59.8M | 0.12 | 24.0% |
| 2017 | CNY 68.2M | 0.16 | 35.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 8, 2022.
Who owns Getein Biotech Inc
- Insiders 46.41%
- Institutions 1.61%
- Public & others 51.98%
- Shares outstanding 507M
- Free float 275M
Getein Biotech Inc company profile
- Company name
- Getein Biotech Inc
- Ticker
- 603387.SHG
- ISIN
- CNE100002RR9
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,733
- Fiscal year end
- December
- Address
- No.9 Bofu Road, Nanjing, China, 211505
- Phone
- 86 25 6856 8588
- Website
- getein.com.cn
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as myocardium, inflammation, renal function, thyroid function, hormones, glucose metabolism, tumor, coagulation, blood cells detection, infectious diseases, autoimmune diseases, universal blocking agents, and secondary antibodies. Getein Biotech, Inc was founded in 2002 and is headquartered in Nanjing, China.
Getein Biotech Inc management
5- Mr. Enben SuChairman & GM · born 1966
- Mr. Wen NiAccounting Supervisor & CFO · born 1983
- Ms. Tingting KongDeputy GM & Director · born 1984
- Mr. Bin YanDeputy GM & Director · born 1982
- Ms. Xu TangBoard Secretary · born 1994